How does tumor stage affect your choice of adjuvant chemotherapy in pancreatic cancer?

I have moved my practice for resectable PDAC (and certainly borderline resectable tumors) almost entirely to neoadjuvant therapy. The SWOG S1505 study (see links below) has shown that either gem/Abraxane or FOLFIRINOX is appropriate. In the adjuvant setting, there is better data for FFX and gem/cis ...